Mainland China

Recognized by WEF as Global Lighthouse Factory, LONGi Leads Smart and Sustainable Manufacturing in the PV Industry

Lighting the Path to Manufacturing Success: LONGi Selected as the Global Lighthouse Network by the World Economic Forum LONGi's Jiaxing Production Base Certified as the World's First "Lighthouse Factory" in the PV Industry XI'AN, China, Jan. 4, 2024 /PRNewswire/ -- LONGi Green Energy Technology ...

2024-01-04 23:48 2373

JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma

SHANGHAI, Jan. 4, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina accepted the ...

2024-01-04 21:40 2533

MAMMOTION Introduces YUKA, 3D Vision Robotic Mower with Self-Emptying Sweeper and Lawn Imagery Printing

Advanced robotic mower cuts grass, clears leaves, and creates customized lawn imagery without perimeter wires SHENZHEN, China, Jan. 4, 2024 /PRNewswire/ -- MAMMOTION, a leader in robotic outdoor solutions, today unveiled the YUKA  - 3D vision robotic lawn mower...

2024-01-04 20:00 3091

Global Times: China-Vietnam maritime cooperation a mutual trust model in safeguarding regional security, stability

BEIJING, Jan. 4, 2024 /PRNewswire/ -- The China Coast Guard (CCG) and the Vietnam Coast Guard (VCG) held the 7th high-level working meeting as well as a series of exchange activities inSouth China's Guangzhou on December 4-8, with both sides vowing to jointly crack down on maritime crime to furth...

2024-01-04 19:33 1952

Maggie Liu Appointed as President of Ringier Trade Media

SHANGHAI, Jan. 4, 2024 /PRNewswire/ -- Maggie Liu will assume the role of President of Ringier Trade Media and Shanghai Ringier Events Co., Ltd., starting January 2, 2024, succeeding the founder Michael R. Hay (Mike). Maggie joined Ringier in 2003, managing the Ringier Guangzhou office. She has h...

2024-01-04 19:06 2039

Pixelworks X7 Gen 2 Visual Processor Makes Debut in OnePlus Ace 3 Smartphone

Delivers Premium Picture Quality Enabled by 120fps and 1.5K Resolution, and Embraces Authentic Game Worlds Powered by End-to-End IRX Gaming Experience SHANGHAI, Jan. 4, 2024 /PRNewswire/ -- Pixelworks, Inc. (NASDAQ: PXLW), a leading provider of visual processing solutions, today announced the new...

2024-01-04 17:00 2430

Miaozhen Academy of Marketing Science Debuts Digital Transformation in Marketing: A Roadmap 2023

BEIJING, Jan. 4, 2024 /PRNewswire/ -- Miaozhen Academy of Marketing Science (MAMS), a Chinese marketing science organization that combines industry expertise, scholarly research and practical insights, has recently unveiled Digital Transformation in Marketing: A Roadmap 2023 ("Roadmap 2023") at th...

2024-01-04 04:30 2636

Yaber is Launching the Latest Innovative Entertainment Projectors at CES

SHENZHEN, China, Jan. 3, 2024 /PRNewswire/ -- Yaber is a leading brand of home entertainment projectors with a global presence, with the vision of bringing cinema-quality entertainment to the world. At Pepcom and CES, Yaber will unveil its latest innovations that will make differences to the home...

2024-01-03 21:09 2580

Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer

DURHAM, N.C., and BEIJING, Jan. 3, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, is pleased to anno...

2024-01-03 20:00 5182

Belief BioMed Successfully Completed Dosing of First Subject in the Registrational Clinical Trial for Hemophilia A

SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- Belief BioMed Group (BBM), an industry-leading biotech company focusing on innovative gene therapies, announced the completion of first subject dosing in its registrational clinical trial (CTR20233400) of BBM-H803, a gene therapy for hemophilia A, independen...

2024-01-03 18:10 1988

To usher in bright future of peace, security, prosperity, progress for world

BEIJING, Jan. 3, 2024 /PRNewswire/ -- A report from People's Daily: The year of 2023 was the first year for fully implementing the guiding principles of the 20th National Congress of the Communist Party of China, and also marked the 10th anniversary of the vision of building a community with a sh...

2024-01-03 17:21 1976

Bilibili New Year's Eve Gala Fuses East & West in Visionary Cultural Spectacle

SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- Bilibili Inc. ("Bilibili" or the "Company"), an iconic brand and leading video community for young people inChina , hosted its fifth consecutive New Year Gala, "The Most Beautiful Night of 2023

2024-01-03 17:05 2033

ZHONGGUO REMITTANCE OFFERS SECURE MONEY TRANSFERS TO CHINA AMID RECENT REGULATORY CHANGES

* Zhongguo Remittance (ZGR) commits to secure money transfers within regulatory frameworks amid recent Monetary Authority ofSingapore (MAS)'s suspensions. * ZGR has completed over 129,223 transactions to China since their partnership with UnionPay in 2015. * As a UnionPay MoneyExpress membe...

2024-01-03 15:50 1874

SolaX Power, a Pioneering Force in Solar and Storage Solutions, Successfully Executes its Initial Public Offering (IPO)

SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- On January 3, 2024, SolaX Power, an industry trailblazer in the solar and storage sector, is pleased to announce the successful culmination of its Initial Public Offering (IPO) and subsequent listing on the Shanghai Stock Exchange STAR Market, trading under ...

2024-01-03 15:30 2931

Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003), a Long-acting cAMP Signaling Biased GLP-1 Analog, in Adult Patients with Type 2 Diabetes in China

* Study participants receiving 0.6 and 1.2 mg ecnoglutide once weekly for 24 weeks achieved HbA1c reductions of 1.96 and 2.43% from baseline, respectively, compared to 0.87 % for placebo * In the 1.2 mg ecnoglutide cohort, 76.1% of participants achieved HbA1c ≤  6.5% and 35.2% achieved HbA1c< ...

2024-01-03 10:00 2461

Macau's Spectacular New Year Concert Sets a New Benchmark in Asian Entertainment at Galaxy Arena

Unleashing Unparalleled Artistry and Technological Marvels Propelling Macau as a City of Performing Arts MACAU, Jan. 2, 2024 /PRNewswire/ -- As 2023 drew to a close, the "2024 JSTV New Year's Eve Concert" illuminated the night inMacau, quickly becoming the focal point of the entertainment industr...

2024-01-03 09:46 2371

USI Upgraded its Intelligent Manufacturing Lights-Off Factory To A New Scale

SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- USI (SSE: 601231), a global leader in electronic design and manufacturing, has announced the new scale of a lights-off factory inShanghai, showcasing remarkable growth in advancing smart manufacturing capabilities. This upgrade, completed at the end of last ...

2024-01-03 07:00 2375

Pulnovo Medical Announces PADN Receives FDA HUD Designation and US CMS Medicare Coverage Code and NMPA Approval

SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized device pioneer in the treatment of Pulmonary Hypertension (PH) and Heart Failure (HF), recently announced that it has successfully obtained Humanitarian Use Device (HUD) designation from the US FDA and approval ...

2024-01-02 20:30 2118

JW Therapeutics Announces Exclusive Collaboration with 2seventy bio for Autoimmune Disease CAR-T Therapy

SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, is pleased to announce an exclusive collaboration with 2seventy bio (NASDAQ: TSVT), for the c...

2024-01-02 20:15 2493

Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis

--Up to 68.2% mean relative reduction in liver fat content from baseline in biopsy-confirmed non-alcoholic steatohepatitis (NASH) patients receiving 12-week treatment of ASC41 tablet --At Week 12, up to 93.3% patients achieved at least a 30% relative reduction in liver fat content from baseline ...

2024-01-02 20:06 2667
1 ... 160161162163164165166 ... 834